Miguel Alcoceba, N/A

Head of Department
Centro de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC), Spain

N/A

Poster(s):

• 1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis